Equine Botulinum Neurotoxin E Immune FAB2 is a mixture of antibodies used to treat documented or suspected botulinum toxin exposure. It is intravenously administered for the treatment of symptomatic botulism following documented or suspected exposure to botulinum neurotoxin serotypes E in adults and pediatric patients.
- Mechanism
- Curator reviewed
Equine Botulinum Neurotoxin E Immune FAB2 is a mix of polyclonal antibodies for botulinum toxin type E. It binds to the toxin with high-affinity and prevents binding to ganglioside anchorage sites and membrane-bound receptors on cholinergic nerve terminals. This prevents internalization of the toxin into the cell and ultimately prevents it from exerting its toxic effects. Due to the long-lasting effects of botulinum toxin, the antibodies must be administered before symptoms present to prevent toxicity.
- Primary indication
- Equine Botulinum Neurotoxin E Immune FAB2 is indicted for use in documented or suspected exposure to botulinum toxin serotype E in adults and pediatric patients.Curator reviewed · 2 structured indications
- First approval
- United States, 2013
- Also known as
- Botulinum Neurotoxin E immune FAB2 (equine) · BOTULINUM NEUROTOXIN E IMMUNE FAB2, EQUINE
- Brand names
Resolves to
What you can answer from here — as of April 02, 2025
Which drugs share a target with Equine Botulinum Neurotoxin E Immune FAB2, and which of those have an active Phase 3 trial?
Create a free account or log in to explore the full data card.
Create Account